Grants are often the launchpad for early-stage Health Tech startups. Schemes like Innovate UK, NIHR, and Horizon Europe fund crucial R&D, clinical trials, and pilot projects. They’re non-dilutive, founder-friendly, and can turn bold ideas into real-world prototypes – especially when traditional investors hesitate.

But here’s the catch: grant funding proves you can run a pilot, not that you can build a business. Too many founders reach the end of a grant cycle only to find themselves stuck. The experiment worked… but where’s the traction? The revenue? The plan for scale?

Investors want more than a proof of concept. They’re looking for evidence that your solution can break out of pilot purgatory and into full-blown adoption – whether that’s via the NHS, private providers or global markets.

Without a clear path from prototype to profit, startups risk falling into the all-too-common funding gap: too late for more grants, too early for VC.

Bridging that gap isn’t easy – but it’s doable. It requires rigorous financial modelling, investor-ready strategy and a brutally honest look at your numbers. In this article, we’ll explore what it really takes to transition from grant-funded research to investor-backed growth – and how to avoid the silent killers of Health Tech momentum. 

Step 1: Understand what grants can and can’t do

Grants are brilliant for:

• Funding R&D, prototypes and clinical trials.
• De-risking early technical development.
• Building partnerships with universities, hospitals and research networks.

But grants can’t:

• Prove a scalable revenue model.
• Convince investors you can win NHS contracts or private healthcare deals.
• Cover the long-term cashflow needs of scaling a regulated business.

Too many Health Tech founders treat grants as if they’re “free money” that will carry them all the way to Series A. The reality is that grants are the first stepping stone, not the bridge. To cross the funding chasm, you need a plan that blends public money with private capital – early.

Step 2: NHS ambitions? Plan for delay

Every Health Tech founder dreams of landing NHS contracts. But the NHS procurement cycle can take 12-24 months – and that’s after pilots, compliance approvals, and stakeholder engagement.

If your financial model assumes fast NHS adoption, investors will see straight through it. Instead, you need to:

• Forecast delays realistically. Build scenarios where NHS deals don’t land for 18-24 months.
• Show parallel private routes. Investors love seeing startups balance NHS pilots with quicker wins in private healthcare, insurance or corporate health providers.
• Tie compliance costs to milestones. Instead of vague “regulatory spend,” show exactly when and why each cost appears (data privacy, clinical validation, CE/UKCA marking).

By grounding your model in the real adoption cycle, you demonstrate credibility. Investors know NHS deals are slow – what they want is proof you’ve planned for it.

Worried your financial model won’t stand up to investor scrutiny? 💡 

Step 3: Translate pilots into a commercial story

Grants often fund pilots, but pilots don’t equal paying contracts. The “pilot trap” is where many Health Tech startups stall.

To convince investors, you need to show:

• Conversion targets. How many pilots do you expect to turn into contracts, and at what percentage rate?
• Pricing clarity. Be transparent about your business model – subscription, pay-per-use, or hybrid.
• Evidence of demand. Collect letters of intent, case studies, or customer testimonials during pilot phases.

This is where many founders trip up. They assume clinical validation will carry the pitch. In reality, investors want both: clinical impact and commercial traction. And they expect you to show how one leads to the other.

Step 4: Build a raise strategy before the grants run out

The most dangerous point for a Health Tech startup is when the last grant payment hits the account and you’re still 6-12 months away from your next round.

To avoid this crunch:

• Model your runway now. Don’t wait until you’re down to three months of cash. Investors hate rushed raises.
• Plan overlapping funding. Start fundraising conversations at least 9 months before your grants end.
• Show blended finance. Angels, early VC, and even non-dilutive debt options can all be part of your strategy.

A clear financial roadmap reassures investors that you’re not sleepwalking into the funding gap. It shows you know exactly how much you need, when, and why. Desperation raises kill credibility. Momentum raises build it.

Step 5: Anticipate investor hot buttons

Every investor looking at a Health Tech startup will test for the same five things:

1. Scalability – Can this work beyond one hospital or one pilot?
2. Compliance readiness – Is regulation mapped into the financials?
3. Unit economics – What does it cost to acquire and serve a customer?
4. Runway – How long until you run out of cash?
5. Profitability path – Even if far off, is there a clear line to break-even?

If your pitch or model doesn’t cover these, investors will assume you’re not ready. The secret is to anticipate the questions and address them upfront.

Bringing it all together

Bridging the Health Tech funding gap isn’t about luck or waiting for the next grant call. It’s about strategic financial planning: knowing when grants stop helping, planning for the NHS adoption cycle, turning pilots into contracts, and raising before the cliff-edge.

At Standard Ledger UK, we work with Health Tech founders to:

• Model cashflow and scenarios around NHS/private adoption.
• Build investor-ready decks that show both clinical impact and commercial viability.
• Support fundraising strategy with SEIS/EIS, valuations, and CFO-level insight.

Because when you can prove the numbers with confidence, investors don’t just see a pilot – they see a well-run, investable company ready to scale.